In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism

被引:13
作者
Allorge, D
Harlow, J
Boulet, O
Hayhurst, GP
Chowdry, J
Roth, E
Crewe, K
Lo-Guidice, JM
Lhermitte, M
Broly, F
Tucker, GT
Ellis, SW
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Unit Mol Pharmacol & Pharmacogenet, Sheffield S10 2JF, S Yorkshire, England
[2] Fac Med Pole Rech, Lille, France
[3] Inst Pasteur, Dept Biol Mol, Unite Genet Differenciat, Paris, France
来源
PHARMACOGENETICS | 2001年 / 11卷 / 08期
关键词
catalytic activity; CYP2D6.35; debrisoquine; ultra-rapid metabolism;
D O I
10.1097/00008571-200111000-00014
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
From 10 to 30% of CYP2D6 ultra-rapid metabolizers of Caucasian origin harbor alleles with duplicated or amplified functional CYP2D6 genes. Recently, the CYP2D6*35 allele has been reported to be more frequent in ultra-rapid metabolizing subjects than in extensive metabolizers, suggesting a possible role of this variant in CYP2D6 duplication-negative ultra-rapid metabolizing subjects. In this study, we examined the functional consequences of the Val(11)Met, Arg(296)Cys and Ser(486)Thr amino acid substitutions associated with the CYP2D6*35 on the expression and catalytic activity of the variant enzyme, heterologously expressed in yeast. Our results indicate that the functional activity and level of expression of recombinant CYP2D6.35 are comparable with those of the wild-type enzyme, thus precluding the hypothesis that the high level of enzyme activity in CYP2D6 duplication-negative ultra-rapid metabolizing subjects is a consequence of the expression of a more catalytically effective CYP2D6.35 enzyme. Pharmacogenetics 11:739-741 (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:739 / 741
页数:3
相关论文
共 11 条
[1]  
Bathum L, 1998, PHARMACOGENETICS, V8, P119
[2]   Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes [J].
Crewe, HK ;
Ellis, SW ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :171-178
[3]  
DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
[4]   Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6 [J].
Ellis, SW ;
Hayhurst, GP ;
Lightfoot, T ;
Smith, G ;
Harlow, J ;
Rowland-Yeo, K ;
Larsson, C ;
Mahling, J ;
Lim, CK ;
Wolf, CR ;
Blackburn, MG ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL JOURNAL, 2000, 345 :565-571
[5]   Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population [J].
Griese, EU ;
Zanger, UM ;
Brudermanns, U ;
Gaedigk, A ;
Mikus, G ;
Morike, K ;
Stuven, T ;
Eichelbaum, M .
PHARMACOGENETICS, 1998, 8 (01) :15-26
[6]   Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6 [J].
Hayhurst, GP ;
Harlow, J ;
Chowdry, J ;
Gross, E ;
Hilton, E ;
Lennard, MS ;
Tucker, GT ;
Ellis, SW .
BIOCHEMICAL JOURNAL, 2001, 355 (02) :373-379
[7]   INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE [J].
JOHANSSON, I ;
LUNDQVIST, E ;
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
INGELMANSUNDBERG, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11825-11829
[8]   Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling [J].
Lightfoot, T ;
Ellis, SW ;
Mahling, J ;
Ackland, MJ ;
Blaney, FE ;
Bijloo, GJ ;
De Groot, MJ ;
Vermeulen, NPE ;
Blackburn, GM ;
Lennard, MS ;
Tucker, GT .
XENOBIOTICA, 2000, 30 (03) :219-233
[9]   Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype:: a role for the CYP2D6*35 allele in ultrarapid metabolism? [J].
Lovlie, R ;
Daly, AK ;
Matre, GE ;
Molven, A ;
Steen, VM .
PHARMACOGENETICS, 2001, 11 (01) :45-55
[10]   Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution [J].
Marez, D ;
Legrand, M ;
Sabbagh, N ;
LoGuidice, JM ;
Spire, C ;
Lafitte, JJ ;
Meyer, UA ;
Broly, F .
PHARMACOGENETICS, 1997, 7 (03) :193-202